These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29422861)

  • 1. The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore.
    Mashaki Ceyhan E; Gürsöz H; Alkan A; Coşkun H; Koyuncu O; Walker S
    Front Pharmacol; 2018; 9():9. PubMed ID: 29422861
    [No Abstract]   [Full Text] [Related]  

  • 2. The Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore.
    Haqaish WSA; Obeidat H; Patel P; Walker S
    Pharmaceut Med; 2017; 31(1):21-30. PubMed ID: 28572733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Performance of the Turkish Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.
    Koyuncu O; Gursoz H; Alkan A; Cetintas HC; Pasaoglu T; Mashaki Ceyhan E; Walker S
    Front Pharmacol; 2019; 10():1557. PubMed ID: 32116658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland.
    Keyter A; Salek S; Banoo S; Walker S
    Front Pharmacol; 2019; 10():228. PubMed ID: 30923501
    [No Abstract]   [Full Text] [Related]  

  • 5. The Saudi Arabia Food and Drug Authority: An Evaluation of the Registration Process and Good Review Practices in Saudi Arabia in Comparison with Australia, Canada and Singapore.
    Hashan H; Aljuffali I; Patel P; Walker S
    Pharmaceut Med; 2016; 30():37-47. PubMed ID: 26834481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of good review practices in member authorities of the East African Medicines Regulatory Harmonisation initiative: strategies for alignment with African medicines agency.
    Ngum N; Ndomondo-Sigonda M; Habonimana R; Siyoi F; Irasabwa C; Ojukwu J; Apolinary F; Okello A; Ahmada S; Walker S; Salek S
    Front Med (Lausanne); 2024; 11():1437970. PubMed ID: 39267958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
    Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
    Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice.
    Rodier C; Bujar M; McAuslane N; Patel P; Liberti L
    Ther Innov Regul Sci; 2021 Jan; 55(1):118-128. PubMed ID: 32617911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the review models and approval timelines of authorities participating in the East African Medicine Regulatory Harmonisation initiative: alignment and strategies for moving forward.
    Ngum N; Ndomondo-Sigonda M; Habonimana R; Siyoi F; Irasabwa C; Ojukwu J; Apolinary F; Okello A; Ahmada S; Walker S; Salek S
    Front Med (Lausanne); 2024; 11():1438041. PubMed ID: 39355848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence.
    Matsuhama M; Takishita T; Kuribayashi R; Takagi K; Wakao R; Mikami K
    J Pharm Pharm Sci; 2016; 19(2):290-301. PubMed ID: 27518176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices.
    Sithole T; Salek S; Mahlangu G; Walker S
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):109-119. PubMed ID: 34645359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.
    Rawson NS
    Can J Clin Pharmacol; 2002; 9(2):73-8. PubMed ID: 12172587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar development and review process in the BRICS-TM countries: Proposal for a standardized model to improve regulatory performance.
    Rahalkar H; Sheppard A; Salek S
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):215-236. PubMed ID: 35078378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Good Review Practices of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.
    Sithole T; Mahlangu G; Capote V; Sitoie T; Shifotoka S; Gaeseb J; Padayachee S; Sehloho T; Khea A; Fimbo A; Munkombwe Z; Mwale B; Salek S; Walker S
    Front Med (Lausanne); 2021; 8():742181. PubMed ID: 34513893
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities.
    Sithole T; Mahlangu G; Salek S; Walker S
    Ther Innov Regul Sci; 2021 May; 55(3):474-489. PubMed ID: 33387356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies.
    Liu LL; McAuslane N; Tzou MC; Chern HD; Liberti L; Ward M; Kang JJ
    Ther Innov Regul Sci; 2013 Nov; 47(6):678-683. PubMed ID: 30235555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effectiveness and Efficiency of the East African Community Joint Assessment Procedure by Member Countries: The Way Forward.
    Ngum N; Mashingia J; Ndomondo-Sigonda M; Walker S; Salek S
    Front Pharmacol; 2022; 13():891506. PubMed ID: 35865962
    [No Abstract]   [Full Text] [Related]  

  • 20. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.
    Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM
    Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.